SG11201700089QA - Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria - Google Patents
Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteriaInfo
- Publication number
- SG11201700089QA SG11201700089QA SG11201700089QA SG11201700089QA SG11201700089QA SG 11201700089Q A SG11201700089Q A SG 11201700089QA SG 11201700089Q A SG11201700089Q A SG 11201700089QA SG 11201700089Q A SG11201700089Q A SG 11201700089QA SG 11201700089Q A SG11201700089Q A SG 11201700089QA
- Authority
- SG
- Singapore
- Prior art keywords
- formulation
- broad
- vaccine against
- basic units
- multiple epitopes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/107—Vibrio
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20141361 | 2014-07-25 | ||
| PCT/EP2015/066988 WO2016012587A1 (fr) | 2014-07-25 | 2015-07-24 | Vaccins glycoconjugués comprenant des motifs de base d'un produit de synthèse moléculaire exprimant des épitopes multiples intégrés pour la formulation d'un vaccin à large spectre contre des infections dues à des bactéries entéropathogènes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700089QA true SG11201700089QA (en) | 2017-02-27 |
Family
ID=51494387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700089QA SG11201700089QA (en) | 2014-07-25 | 2015-07-24 | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10500263B2 (fr) |
| EP (1) | EP3174553B1 (fr) |
| CN (1) | CN106659799B (fr) |
| CA (1) | CA2954087C (fr) |
| DK (1) | DK3174553T3 (fr) |
| EA (1) | EA035556B1 (fr) |
| ES (1) | ES2672045T3 (fr) |
| HU (1) | HUE038212T2 (fr) |
| SG (1) | SG11201700089QA (fr) |
| WO (1) | WO2016012587A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2672045T3 (es) * | 2014-07-25 | 2018-06-12 | Biosynth S.R.L. | Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas |
| JP6992057B2 (ja) | 2016-06-10 | 2022-01-13 | クラリティ コスメティックス インコーポレイテッド | 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法 |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| MX2022016587A (es) * | 2020-06-18 | 2023-02-01 | Glaxosmithkline Biologicals Sa | Bioconjugado tetravalente de shigella (shigella4v). |
| WO2022216734A1 (fr) * | 2021-04-06 | 2022-10-13 | The Board Of Trustees Of The University Of Illinois | Antigène de fusion multi-épitope (mefa) de choléra multivalent et méthodes d'utilisation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US203143A (en) * | 1878-04-30 | Improvement in embroidering-machines | ||
| IT1187753B (it) * | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US5919463A (en) * | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
| US6951652B2 (en) * | 1998-07-29 | 2005-10-04 | Biosynth S.R.L. | Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases |
| AU781027B2 (en) * | 1999-04-09 | 2005-04-28 | Department Of Health & Human Services | Recombinant toxin a protein carrier for polysaccharide conjugate vaccines |
| WO2003094961A1 (fr) * | 2002-05-09 | 2003-11-20 | Massimo Porro | Vaccins de polysaccharides et de glycoconjugues ameliores |
| AU2002368447A1 (en) * | 2002-12-06 | 2004-06-30 | Biosynth S.R.L. | Broad-spectrum lps based vaccines of unencapsulated strains ofhaemophilus influenzae and other pathogenic species of gram-negative bacteria |
| CA2514328C (fr) * | 2003-01-30 | 2020-01-14 | Chiron Srl | Vaccins injectables contre les multiples serogroupes du meningocoque |
| US7507718B2 (en) | 2005-04-11 | 2009-03-24 | Sanofi Pasteur | Polymyxin B analogs for LPS detoxification |
| JP2009521434A (ja) * | 2005-12-22 | 2009-06-04 | サノフィ パストゥール インコーポレイテッド | 髄膜炎菌由来の誘導体化多糖類−タンパク質の多価コンジュゲートおよびワクチン |
| GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| ES2528648T3 (es) * | 2007-09-11 | 2015-02-11 | University Of Guelph | Inmunógenos polisacáridos de la Clostridium Difficile |
| US20120020996A1 (en) * | 2008-08-06 | 2012-01-26 | Jonathan Lewis Telfer | Vaccines against clostridium difficile and methods of use |
| GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| BR122019017005B1 (pt) * | 2011-04-22 | 2022-03-29 | Wyeth Llc | Composições que se relacionam a uma toxina de clostridium difficile mutante |
| US9815889B2 (en) * | 2011-08-02 | 2017-11-14 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Antibodies for prevention and treatment of diseases caused by clostridium difficile |
| EP2554549A1 (fr) * | 2011-08-02 | 2013-02-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Oligosaccharides et conjugués de protéine d'oligosaccharides dérivés de PS-I de polysaccharide difficile de Clostridium, procédés de synthèse et utilisations associées, en particulier en tant que vaccins et outils de diagnostic |
| CA3107450A1 (fr) * | 2012-03-29 | 2013-10-03 | Therabiome, Llc | Formulations de vaccination orale specifiques a un site gastro-intestinal actives sur l'ileon et l'appendice |
| WO2014059296A1 (fr) * | 2012-10-12 | 2014-04-17 | Department Of Veterans Affairs | Vaccin atténué à base de tcda et tcdb de toxines clostridiales et d'ehec contre une maladie à clostridium difficile |
| AU2013338153B2 (en) * | 2012-10-29 | 2018-06-21 | The Board Of Trustees Of The University Of Arkansas | Novel mucosal adjuvants and delivery systems |
| EP2915347A1 (fr) * | 2012-11-02 | 2015-09-09 | Telefonaktiebolaget LM Ericsson (PUBL) | Procédés, module de gestion de transmission, et équipement d'utilisateur, pour gérer un contenu numérique dans un réseau de communication cellulaire |
| JP6290918B2 (ja) * | 2012-12-05 | 2018-03-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| ITMI20130142A1 (it) | 2013-01-31 | 2014-08-01 | Biosynth Srl | Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati |
| CN110917220A (zh) * | 2013-02-04 | 2020-03-27 | 赛里斯治疗公司 | 治疗组合物及其使用方法 |
| PL404229A1 (pl) * | 2013-06-06 | 2014-12-08 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością | Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie |
| WO2015100409A2 (fr) * | 2013-12-26 | 2015-07-02 | Tufts University | Procédés, compositions et kits de traitement d'un sujet à l'aide d'une protéine de liaison neutralisante recombinante |
| ES2672045T3 (es) * | 2014-07-25 | 2018-06-12 | Biosynth S.R.L. | Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas |
| EP4070815A1 (fr) * | 2016-10-03 | 2022-10-12 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Immunogènes de peptides de fusion env du vih-1 et leur utilisation |
-
2015
- 2015-07-24 ES ES15742232.0T patent/ES2672045T3/es active Active
- 2015-07-24 EA EA201692546A patent/EA035556B1/ru not_active IP Right Cessation
- 2015-07-24 DK DK15742232.0T patent/DK3174553T3/en active
- 2015-07-24 HU HUE15742232A patent/HUE038212T2/hu unknown
- 2015-07-24 US US15/329,205 patent/US10500263B2/en active Active
- 2015-07-24 CN CN201580039496.6A patent/CN106659799B/zh active Active
- 2015-07-24 EP EP15742232.0A patent/EP3174553B1/fr active Active
- 2015-07-24 WO PCT/EP2015/066988 patent/WO2016012587A1/fr active Application Filing
- 2015-07-24 CA CA2954087A patent/CA2954087C/fr active Active
- 2015-07-24 SG SG11201700089QA patent/SG11201700089QA/en unknown
-
2019
- 2019-10-28 US US16/666,367 patent/US11246919B2/en active Active
-
2021
- 2021-01-25 US US17/157,969 patent/US11576959B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11246919B2 (en) | 2022-02-15 |
| EA201692546A1 (ru) | 2017-08-31 |
| CN106659799A (zh) | 2017-05-10 |
| US20170209563A1 (en) | 2017-07-27 |
| CA2954087C (fr) | 2023-09-19 |
| HUE038212T2 (hu) | 2018-10-29 |
| US11576959B2 (en) | 2023-02-14 |
| EP3174553A1 (fr) | 2017-06-07 |
| ES2672045T3 (es) | 2018-06-12 |
| US20200129606A1 (en) | 2020-04-30 |
| US10500263B2 (en) | 2019-12-10 |
| DK3174553T3 (en) | 2018-07-23 |
| CN106659799B (zh) | 2020-07-17 |
| EP3174553B1 (fr) | 2018-04-18 |
| EA035556B1 (ru) | 2020-07-07 |
| CA2954087A1 (fr) | 2016-01-28 |
| WO2016012587A1 (fr) | 2016-01-28 |
| US20210138059A1 (en) | 2021-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201607627B (en) | Vaccine composition against streptococcus suis infection | |
| HK1211224A1 (en) | Multivalent glycoconjugate vaccines | |
| ZA201708713B (en) | Multivalent pneumococcal conjugate vaccine | |
| ZA201604498B (en) | Single vial vaccine formulations | |
| ZA201608487B (en) | Dual adjuvant vaccine compositions, preparation and uses | |
| SG11201700089QA (en) | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria | |
| GB201301085D0 (en) | Glycoconjugate Vaccine | |
| SG11201702298VA (en) | Pharmaceutical preparation | |
| ZA201607355B (en) | Group a streptococcus vaccine | |
| IL248855B (en) | S-pyralindole and its pharmaceutically acceptable salts for use in medicine | |
| HK1258252A1 (zh) | 腺嘌呤綴合物化合物及其作為疫苗佐劑的用途 | |
| PL3256154T3 (pl) | Preparat farmaceutyczny zawierający przeciwciało | |
| GB201701400D0 (en) | Compound for use in medicine | |
| IL243432A0 (en) | Synthetic oligosaccharides for vaccination against p. aeruginosa and uses thereof | |
| EP3166957A4 (fr) | Glycolipides sulfatés comme adjuvants de vaccins | |
| HUE063529T2 (hu) | Szélesspektrumú vakcina madár reovírus ellen | |
| EP3189852A4 (fr) | Composition pharmaceutique vaccinale renfermant un bisphosphonate, destinée à induire l'immunité humorale | |
| EP3379974A4 (fr) | Ensemble de transfert de patient couché | |
| GB201616880D0 (en) | Compound for use in medicine | |
| GB201701388D0 (en) | Compound for use in medicine | |
| UA27369S (uk) | Розгортка упаковки для чаю «домашній» | |
| UA30852S (uk) | Розгортка упаковки для чаю «аskold» |